EIGER BIOPHARMACEUTICALS, INC.

PALO ALTO, CA How do I update this listing?

Eiger Biopharmaceuticals is based out of Palo Alto. Celadon Group, Inc. (Celadon) is engaged in the business of truckload carriers. As a dry van truckload carrier, the Company transports full trailer loads of freight from origin to destination without intermediate stops or handling. It operates in two segments: asset-based segment and an asset-light segment. The Company���s asset-based segment includes its asset-based dry van carrier and rail services, which are geographically diversified but have similar economic and other relevant characteristics, as they all provide truckload carrier services of general commodities to a similar class of customers. Its asset-light segment consists of its warehousing, brokerage, and less-than-load (LTL) operations, as well as its interest in Truckers B2B. In February 2012, the Company���s wholly owned subsidiary, Celadon Trucking Services, Inc. purchased a portion of the operating equipment of Teton Transportation, Inc. (Teton).Whalewisdom has at least 122 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2016-04-29. The notice included securities offered of Equity

Create Alert

Contact Info

eiger biopharmaceuticals, inc.
2155 PARK BOULEVARD
PALO ALTO CA    94306

Business Phone: 650-279-9845
SEC SIC CODE:
2836-BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2016-04-29 D BIOTECHNOLOGY Equity 3,000,000 2,999,982 18
2013-10-25 D BIOTECHNOLOGY Debt,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 2,397,417 1,097,306 1,300,111
2012-05-08 D/A BIOTECHNOLOGY Equity,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 64,537,095 19,466,190 45,070,905
2012-02-06 D BIOTECHNOLOGY Equity 61,349,995 17,849,996 43,499,999
2011-12-22 D BIOTECHNOLOGY Debt,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 500,000 500,000 0
2011-11-16 D BIOTECHNOLOGY Debt,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 500,000 330,000 170,000
2011-10-28 D BIOTECHNOLOGY Debt,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 200,000 200,000 0
2011-09-01 D BIOTECHNOLOGY Debt,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 250,000 250,000 0
2011-07-12 D PHARMACEUTICALS Debt,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 400,000 400,000 0
2010-10-28 D PHARMACEUTICALS Debt,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 4,000,000 2,500,000 1,500,000
2009-12-17 D PHARMACEUTICALS Debt,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 6,500,000 3,500,000 3,000,000
2009-09-10 D/A PHARMACEUTICALS Equity,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 24,631,114 21,800,002 2,831,112
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
ANDREW E. SENYEI subscription required
    DIRECTOR
ANTHONY B. EVNIN subscription required
    DIRECTOR
ASISH XAVIER subscription required
    DIRECTOR
BARBARA DALTON subscription required
    DIRECTOR
CHARLES BRAMLAGE subscription required
    DIRECTOR
DANIEL OMSTEAD subscription required
    DIRECTOR
DAVID A. CORY subscription required
    EXECUTIVE OFFICER DIRECTOR
EDGAR G. ENGLEMAN subscription required
    DIRECTOR
EDUARDO BRUNO MARTINS subscription required
    EXECUTIVE OFFICER
FOUAD AZZAM subscription required
    DIRECTOR
GRAHAM COOPER subscription required
    DIRECTOR
GREGG ALTON subscription required
    DIRECTOR
JAMES P. SHAFFER subscription required
    EXECUTIVE OFFICER
JAMES H. WELCH subscription required
    EXECUTIVE OFFICER
JEFFREY S. GLENN subscription required
    DIRECTOR
JOANNE QUAN subscription required
    EXECUTIVE OFFICER
JOHAN KORDEL subscription required
    DIRECTOR
JOSHUA FUNDER subscription required
    DIRECTOR
KENNETH R. CHIEN subscription required
    DIRECTOR
KRISZTINA ZSEBO subscription required
    EXECUTIVE OFFICER DIRECTOR
LAUREN SILVERMAN subscription required
    DIRECTOR
MICHAEL NARACHI subscription required
    DIRECTOR
NINA KJELLSON subscription required
    DIRECTOR
REBECQUE LABA subscription required
    EXECUTIVE OFFICER
THOMAS J. DIETZ subscription required
    DIRECTOR
TODD FOLEY subscription required
    DIRECTOR

Elevate your investments